Today it was reported that the EVP of Zoetis (ZTS), Kristin Peck, exercised options to sell 11,500 ZTS shares for a total transaction value of $1.09M.
Following Kristin Peck’s last ZTS Sell transaction on November 23, 2016, the stock climbed by 44.8%. In addition to Kristin Peck, one other ZTS executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Zoetis’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.48 billion and quarterly net profit of $347 million. In comparison, last year the company earned revenue of $1.35 billion and had a net profit of $298 million. ZTS’s market cap is $45.42B and the company has a P/E ratio of 39.68. Currently, Zoetis has an average volume of 1.74M.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $101.43, reflecting a 7.7% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
